Hypomagnesemia associated with a proton pump inhibitor

Internal Medicine

Volumn 51, Issue 16, 2012, Pages 2231-2234

  Matsuyama, Jun ^a   Tsuji, Kunihiro ^a   Doyama, Hisashi ^a   Kim, Fae ^a   Takeda, Yasuhito ^a   Kito, Yosuke ^a   Ito, Renma ^a   Nakanishi, Hiroyoshi ^a   Hayashi, Tomoyuki ^a   Waseda, Yohei ^a   Tsuji, Shigetsugu ^a   Takemura, Kenichi ^a   Yamada, Shinya ^a   Okada, Toshihide ^a   Kanaya, Honin ^a  

^a ISHIKAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Hypomagnesemia; Japan; Japanese; PPI; Proton pump inhibitor; Rabeprazole

Indexed keywords

C REACTIVE PROTEIN; CALCIUM; MAGNESIUM; POTASSIUM; RABEPRAZOLE;

ADULT; ARTHRITIS; ARTICLE; CASE REPORT; COLON TUMOR; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CONVULSION; DRUG WITHDRAWAL; EDEMA; FEVER; GASTROESOPHAGEAL REFLUX; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; LIMB TREMOR; MALE; NAUSEA; PSEUDOGOUT;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; GASTROESOPHAGEAL REFLUX; HUMANS; MAGNESIUM; MAGNESIUM DEFICIENCY; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS;

EID: 84865148966     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.7748     Document Type: Article

References (18)

1. Forgacs I, Loganayagan A. Overprescribing proton pump inhibitors. BMJ 336: 2-3, 2008.
2. Epstein M, McGrath S, Law F. Proton pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 355: 1834-1836, 2006.
3. Kuipers MT, Thang HD, Arntzenius AB. Hypomagnesaemia due to use of proton pump inhibitors-a review. Neth J Med 67: 169-172, 2009.
4. Rockville MD. Proton pump inhibitor drugs (PPIs): Drug Safety Communication-low magnesium levels can be associated with long-term use: US Food and Drug Administration, 2011.
5. Noronha JL, Matuschak GM. Magnesium in critical illness: metabolism, assessment and treatment. Intensive Care Med 28: 667-679, 2002.
6. Cundy T, Mackay J. Proton pump inhibitors and severe hypomagnesaemia. Curr Opin Gastroenterol 27: 180-185, 2011.
7. Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf) 69: 338-341, 2008.
8. Shabajee N, Lamb EJ, Sturgess I, Sumathipala RW. Omeprazole and refractory hypomagnesaemia. BMJ 337: a425, 2008.
9. Hoorn EJ, van der Hoek J, de Man RA, Kuipers EJ, Bolwerk C, Zietse R. A case series of proton pump inhibitor-induced hypo-magnesemia. Am J Kidney Dis 56: 112-116, 2010.
10. Mackay JD, Bladon PT. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. QJM 103: 387-395, 2010.
11. Jones AC, Chuck AJ, Arie EA, Green DJ, Dohrerty M. Diseases associated with calcium pyrophosphate deposition disease. Semin Arthritis Rheum 22: 188-202, 1992.
12. Mouchantaf R. Proton pump inhibitors: hypomagnesemia accompanied by hypocalcemia and hypokalemia. Can Adverse Reaction Newsletter 2011 21: 2011.
13. Furlanetto TW, Faulhaber GA. Hypomagnesemia and proton pump inhibitors: below the tip of the iceberg. Arch Intern Med 171: 1391-1392, 2011.
14. Broeren MA, Geerdink EA, Vader HL, et al. Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med 151: 755-756, 2009.
15. Regolisti G, Cabassi A, Parenti E, et al. Severe hypomagnesemia during long-term treatment with a proton pump inhibitor. Am J Kidney Dis 56: 168-174, 2010.
16. Quamme GA. Recent developments in intestinal magnesium absorption. Curr Opin Gastroenterol 24: 230-235, 2008.
17. Li M, Jiang J, Yue L. Functional characterization of homo-and heteromeric channel kinases TRPM6 and TRPM7. J Gen Physiol 127: 525-537, 2006.
18. Mullin JM, Valenzano MC, Whitby M, et al. Esomeprazole induces upper gastrointestinal tract transmucosal permeability increase. Aliment Pharmacol Ther 28: 1317-1325, 2008.